

SEQUENCE LISTING

<110> University of Pittsburgh - of the Commonwealth System of
Higher Education

<120> IRF MODULATOR-EXPRESSING ONCOLYTIC VIRUSES FOR TREATING CANCER

<130> 072396.0849

<150> US 62/985,979

<151> 2020-03-06

<160> 2

<170> PatentIn version 3.5

<210> 1

<211> 349

<212> PRT

<213> Homo sapiens

<400> 1

Met Pro Val Glu Arg Met Arg Met Arg Pro Trp Leu Glu Glu Gln Ile
1 5 10 15

Asn Ser Asn Thr Ile Pro Gly Leu Lys Trp Leu Asn Lys Glu Lys Lys
20 25 30

Ile Phe Gln Ile Pro Trp Met His Ala Ala Arg His Gly Trp Asp Val
35 40 45

Glu Lys Asp Ala Pro Leu Phe Arg Asn Trp Ala Ile His Thr Gly Lys
50 55 60

His Gln Pro Gly Val Asp Lys Pro Asp Pro Lys Thr Trp Lys Ala Asn
65 70 75 80

Phe Arg Cys Ala Met Asn Ser Leu Pro Asp Ile Glu Glu Val Lys Asp
85 90 95

Lys Ser Ile Lys Lys Gly Asn Asn Ala Phe Arg Val Tyr Arg Met Leu
100 105 110

Pro Leu Ser Glu Arg Pro Ser Lys Lys Gly Lys Lys Pro Lys Thr Glu
115 120 125

Lys Glu Asp Lys Val Lys His Ile Lys Gln Glu Pro Val Glu Ser Ser
130 135 140

Leu Gly Leu Ser Asn Gly Val Ser Asp Leu Ser Pro Glu Tyr Ala Val
145 150 155 160

Leu Thr Ser Thr Ile Lys Asn Glu Val Asp Ser Thr Val Asn Ile Ile
165 170 175

Val Val Gly Gln Ser His Leu Asp Ser Asn Ile Glu Asn Gln Glu Ile
180 185 190

Val Thr Asn Pro Pro Asp Ile Cys Gln Val Val Glu Val Thr Thr Glu
195 200 205

Ser Asp Glu Gln Pro Val Ser Met Ser Glu Leu Tyr Pro Leu Gln Ile
210 215 220

Ser Pro Val Ser Ser Tyr Ala Glu Ser Glu Thr Thr Asp Ser Val Pro
225 230 235 240

Ser Asp Glu Glu Ser Ala Glu Gly Arg Pro His Trp Arg Lys Arg Asn
245 250 255

Ile Glu Gly Lys Gln Tyr Leu Ser Asn Met Gly Thr Arg Gly Ser Tyr
260 265 270

Leu Leu Pro Gly Met Ala Ser Phe Val Thr Ser Asn Lys Pro Asp Leu
275 280 285

Gln Val Thr Ile Lys Glu Glu Ser Asn Pro Val Pro Tyr Asn Ser Ser
290 295 300

Trp Pro Pro Phe Gln Asp Leu Pro Leu Ser Ser Ser Met Thr Pro Ala

305 310 315 320

Ser Ser Ser Ser Arg Pro Asp Arg Glu Thr Arg Ala Ser Val Ile Lys
325 330 335

Lys Thr Ser Asp Ile Thr Gln Ala Arg Val Lys Ser Cys
340 345

<210> 2
<211> 346
<212> PRT
<213> Homo sapiens

<400> 2

Met Pro Val Glu Arg Met Arg Met Arg Pro Trp Leu Glu Glu Gln Ile
1 5 10 15

Asn Ser Asn Thr Ile Pro Gly Leu Lys Trp Leu Asn Lys Glu Lys Lys
20 25 30

Ile Phe Gln Ile Pro Trp Met His Ala Ala Arg His Gly Trp Asp Val
35 40 45

Glu Lys Asp Ala Pro Leu Phe Arg Asn Trp Ala Ile His Thr Gly Lys
50 55 60

His Gln Pro Gly Ile Asp Lys Pro Asp Pro Lys Thr Trp Lys Ala Asn
65 70 75 80

Phe Arg Cys Ala Met Asn Ser Leu Pro Asp Ile Glu Glu Val Lys Asp
85 90 95

Arg Ser Ile Lys Lys Gly Asn Asn Ala Phe Arg Val Tyr Arg Met Leu
100 105 110

Pro Leu Ser Glu Arg Pro Ser Lys Lys Gly Lys Lys Pro Lys Thr Glu
115 120 125

Lys Glu Glu Arg Val Lys His Ile Lys Gln Glu Pro Val Glu Ser Ser
130 135 140

Leu Gly Leu Ser Asn Gly Val Ser Gly Phe Ser Pro Glu Tyr Ala Val
145 150 155 160

Leu Thr Ser Ala Ile Lys Asn Glu Val Asp Ser Thr Val Asn Ile Ile
165 170 175

Val Val Gly Gln Ser His Leu Asp Ser Asn Ile Glu Asp Gln Glu Ile
180 185 190

Val Thr Asn Pro Pro Asp Ile Cys Gln Val Val Glu Val Thr Thr Glu
195 200 205

Ser Asp Asp Gln Pro Val Ser Met Ser Glu Leu Tyr Pro Leu Gln Ile
210 215 220

Ser Pro Val Ser Ser Tyr Ala Glu Ser Glu Thr Thr Asp Ser Val Ala
225 230 235 240

Ser Asp Glu Glu Asn Ala Glu Gly Arg Pro His Trp Arg Lys Arg Ser
245 250 255

Ile Glu Gly Lys Gln Tyr Leu Ser Asn Met Gly Thr Arg Asn Thr Tyr
260 265 270

Leu Leu Pro Ser Met Ala Thr Phe Val Thr Ser Asn Lys Pro Asp Leu
275 280 285

Gln Val Thr Ile Lys Glu Asp Ser Cys Pro Met Pro Tyr Asn Ser Ser
290 295 300

Trp Pro Pro Phe Thr Asp Leu Pro Leu Pro Ala Pro Val Thr Pro Thr
305 310 315 320

Pro Ser Ser Ser Arg Pro Asp Arg Glu Thr Arg Ala Ser Val Ile Lys
325 330 335

Lys Thr Ser Asp Ile Thr Gln Ala Arg Val
340 345